|
1
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Hu K, Ding P, Wu Y, Tian W, Pan T and
Zhang S: Global patterns and trends in the breast cancer incidence
and mortality according to sociodemographic indices: An
observational study based on the global burden of diseases. BMJ
Open. 9(e028461)2019.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Foulkes WD, Smith IE and Reis-Filho JS:
Triple-negative breast cancer. N Engl J Med. 363:1938–1948.
2010.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Malorni L, Shetty PB, De Angelis C,
Hilsenbeck S, Rimawi MF, Elledge R, Osborne CK, De Placido S and
Arpino G: Clinical and biologic features of triple-negative breast
cancers in a large cohort of patients with long-term follow-up.
Breast Cancer Res Treat. 136:795–804. 2012.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Bianchini G, Balko JM, Mayer IA, Sanders
ME and Gianni L: Triple-negative breast cancer: Challenges and
opportunities of a heterogeneous disease. Nat Rev Clin Oncol.
13:674–690. 2016.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Carey LA, Dees EC, Sawyer L, Gatti L,
Moore DT, Collichio F, Ollila DW, Sartor CI, Graham ML and Perou
CM: The triple negative paradox: Primary tumor chemosensitivity of
breast cancer subtypes. Clin Cancer Res. 13:2329–2334.
2007.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Liedtke C, Mazouni C, Hess KR, André F,
Tordai A, Mejia JA, Symmans WF, Gonzalez-Angulo AM, Hennessy B,
Green M, et al: Response to neoadjuvant therapy and long-term
survival in patients with triple-negative breast cancer. J Clin
Oncol. 26:1275–1281. 2008.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Nogi H, Kobayashi T, Suzuki M, Tabei I,
Kawase K, Toriumi Y, Fukushima H and Uchida K: EGFR as paradoxical
predictor of chemosensitivity and outcome among triple-negative
breast cancer. Oncol Rep. 21:413–417. 2009.PubMed/NCBI
|
|
9
|
von Minckwitz G, Untch M, Blohmer JU,
Costa SD, Eidtmann H, Fasching PA, Gerber B, Eiermann W, Hilfrich
J, Huober J, et al: Definition and impact of pathologic complete
response on prognosis after neoadjuvant chemotherapy in various
intrinsic breast cancer subtypes. J Clin Oncol. 30:1796–1804.
2012.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Hahnen E, Lederer B, Hauke J, Loibl S,
Kröber S, Schneeweiss A, Denkert C, Fasching PA, Blohmer JU,
Jackisch C, et al: Germline mutation status, pathological complete
response, and disease-free survival in triple-negative breast
cancer: Secondary analysis of the GeparSixto randomized clinical
trial affiliations expand. JAMA Oncol. 3:1378–1385. 2017.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Bonnefoi H, Litière S, Piccart M,
MacGrogan G, Fumoleau P, Brain E, Petit T, Rouanet P, Jassem J,
Moldovan C, et al: Pathological complete response after neoadjuvant
chemotherapy is an independent predictive factor irrespective of
simplified breast cancer intrinsic subtypes: A landmark and
two-step approach analyses from the EORTC 10994/BIG 1-00 phase III
trial. Ann Oncol. 25:1128–1136. 2014.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Cortazar P, Zhang L, Untch M, Mehta K,
Costantino JP, Wolmark N, Bonnefoi H, Cameron D, Gianni L,
Valagussa P, et al: Pathological complete response and long-term
clinical benefit in breast cancer: The CTNeoBC pooled analysis.
Lancet. 384:164–172. 2014.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Kuroi K, Toi M, Ohno S, Nakamura S, Iwata
H, Masuda N, Sato N, Tsuda H, Kurosumi M and Akiyama F: Prognostic
significance of subtype and pathologic response in operable breast
cancer; a pooled analysis of prospective neoadjuvant studies of
JBCRG. Breast Cancer. 22:486–495. 2015.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Perou CM, Sørlie T, Eisen MB, van de Rijn
M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA,
et al: Molecular portraits of human breast tumours. Nature.
406:747–572. 2000.PubMed/NCBI View
Article : Google Scholar
|
|
15
|
Sørlie T, Perou CM, Tibshirani R, Aas T,
Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey
SS, et al: Gene expression patterns of breast carcinomas
distinguish tumor subclasses with clinical implications. Proc Natl
Acad Sci USA. 98:10869–10874. 2001.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Herschkowitz JI, Simin K, Weigman VJ,
Mikaelian I, Usary J, Hu Z, Rasmussen KE, Jones LP, Assefnia S,
Chandrasekharan S, et al: Identification of conserved gene
expression features between murine mammary carcinoma models and
human breast tumors. Genome Biol. 8(R76)2007.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Prat A, Parker JS, Karginova O, Fan C,
Livasy C, Herschkowitz JI, He X and Perou CM: Phenotypic and
molecular characterization of the claudin-low intrinsic subtype of
breast cancer. Breast Cancer Res. 12(R68)2010.PubMed/NCBI View
Article : Google Scholar
|
|
18
|
Ding L, Lu Z, Lu Q and Chen YH: The
claudin family of proteins in human malignancy: A clinical
perspective. Cancer Manag Res. 5:367–375. 2013.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Lehmann BD, Bauer JA, Chen X, Sanders ME,
Chakravarthy AB, Shyr Y and Pietenpol JA: Identification of human
triple-negative breast cancer subtypes and preclinical models for
selection of targeted therapies. J Clin Invest. 121:2750–2767.
2011.PubMed/NCBI View
Article : Google Scholar
|
|
20
|
Masuda H, Baggerly KA, Wang Y, Zhang Y,
Gonzalez-Angulo AM, Meric-Bernstam F, Valero V, Lehmann BD,
Pietenpol JA, Hortobagyi GN, et al: Differential response to
neoadjuvant chemotherapy among 7 triple-negative breast cancer
molecular subtypes. Clin Cancer Res. 19:5533–5540. 2013.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Lehmann BD, Jovanović B, Chen X, Estrada
MV, Johnson KN, Shyr Y, Moses HL, Sanders ME and Pietenpol JA:
Refinement of triple-negative breast cancer molecular subtypes:
Implications for neoadjuvant chemotherapy selection. PLoS One.
11(e0157368)2016.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Masuda N, Lee SJ, Ohtani S, Im YH, Lee ES,
Yokota I, Kuroi K, Im SA, Park BW, Kim SB, et al: Adjuvant
capecitabine for breast cancer after preoperative chemotherapy. N
Engl J Med. 376:2147–2159. 2017.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Denkert C, Liedtke C, Tutt A and von
Minckwitz G: Molecular alterations in triple-negative breast
cancer-the road to new treatment strategies. Lancet. 389:2430–2442.
2017.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Schmid P, Adams S, Rugo HS, Schneeweiss A,
Barrios CH, Iwata H, Diéras V, Hegg R, Im SA, Shaw Wright G, et al:
Atezolizumab and nab-paclitaxel in advanced triple-negative breast
cancer. N Engl J Med. 379:2108–2121. 2018.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Damaskos C, Garmpi A, Nikolettos K,
Vavourakis M, Diamantis E, Patsouras A, Farmaki P, Nonni A,
Dimitroulis D, Mantas D, et al: Triple-negative breast cancer: The
progress of targeted therapies and future tendencies. Anticancer
Res. 39:5285–5296. 2019.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Nedeljković M and Damjanović A: Mechanisms
of chemotherapy resistance in triple-negative breast cancer-how we
can rise to the challenge. Cells. 8(957)2019.PubMed/NCBI View Article : Google Scholar
|
